Oncternal Therapeutics (ONCT) News Today → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free ONCT Stock Alerts $8.18 -0.46 (-5.32%) (As of 05/10/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineOncternal Therapeutics, Inc. (NASDAQ:ONCT) Q1 2024 Earnings Call Transcriptmsn.com - May 11 at 8:37 AMOncternal Therapeutics (NASDAQ:ONCT) Earns Hold Rating from Analysts at StockNews.comamericanbankingnews.com - May 11 at 3:10 AMQ1 2024 Oncternal Therapeutics Inc Earnings Callfinance.yahoo.com - May 10 at 12:34 PMONCT Stock Earnings: Oncternal Therapeutics Beats EPS, Beats Revenue for Q1 2024msn.com - May 9 at 9:33 PMOncternal Therapeutics: Q1 Earnings Snapshotsfgate.com - May 9 at 4:33 PMOncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Resultsglobenewswire.com - May 9 at 4:01 PMOncternal Therapeutics earnings: here's what Wall Street expectsmarkets.businessinsider.com - May 8 at 3:30 PMOncternal Therapeutics (ONCT) Scheduled to Post Quarterly Earnings on Thursdayamericanbankingnews.com - May 8 at 5:34 AMOppenheimer Keeps Their Buy Rating on Vertex Pharmaceuticals (VRTX)markets.businessinsider.com - May 7 at 2:15 PMOncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated at StockNews.comamericanbankingnews.com - May 3 at 2:22 AMOncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial Resultsglobenewswire.com - May 2 at 4:05 PMOncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com - May 1 at 9:00 AMAnalysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR) and Addus Homecare (ADUS)markets.businessinsider.com - April 23 at 6:53 PMEwing Sarcoma Drug Pipeline Market Research 2024: Insights About 25+ Companies and 25+ Pipeline Drugsuk.finance.yahoo.com - April 19 at 3:28 PMOncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancerglobenewswire.com - April 18 at 9:00 AMOppenheimer Reaffirms Their Hold Rating on Oncternal Therapeutics (ONCT)markets.businessinsider.com - April 17 at 2:17 PMBuy Rating Affirmed for Oncternal Therapeutics with Adjusted Price Target Amid Positive Financials and Upcoming Catalystsmarkets.businessinsider.com - April 15 at 7:00 PM5 Buy-Rated Stocks with Latest Insider Purchasesinsidermonkey.com - April 14 at 3:02 PMAIVITA Biomedical CEO Dr. Hans Keirstead and CMO Dr. Robert Dillman to Speak and Participate in Keynote Panel at Festival of Biologics USAfinance.yahoo.com - April 11 at 8:44 PMOncternal Therapeutics, Inc. (NASDAQ:ONCT) Director Acquires $27,650.56 in Stockinsidertrades.com - April 11 at 6:48 AMOncternal Therapeutics, Inc. (NASDAQ:ONCT) Director Robert James Wills Purchases 6,914 Sharesinsidertrades.com - April 2 at 4:26 AMOncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancerglobenewswire.com - March 15 at 9:00 AMNorthland Securities Keeps Their Buy Rating on Heron Therapeutics (HRTX)markets.businessinsider.com - March 13 at 1:49 PMOncternal Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Linefinance.yahoo.com - March 10 at 3:41 PMQ4 2023 Oncternal Therapeutics Inc Earnings Callfinance.yahoo.com - March 8 at 11:39 AMOncternal Therapeutics, Inc. (NASDAQ:ONCT) Q4 2023 Earnings Call Transcriptmsn.com - March 8 at 11:39 AMOncternal Therapeutics's Earnings: A Previewbenzinga.com - March 8 at 6:38 AMONCT Stock Earnings: Oncternal Therapeutics Misses EPS, Beats Revenue for Q4 2023msn.com - March 7 at 10:45 PMRecap: Oncternal Therapeutics Q4 Earningsbenzinga.com - March 7 at 5:45 PMOncternal Therapeutics: Q4 Earnings Snapshotwashingtonpost.com - March 7 at 5:45 PMOncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Resultsglobenewswire.com - March 7 at 4:01 PMOncternal Therapeutics earnings: here's what to expectmarkets.businessinsider.com - March 6 at 4:42 PMOncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Resultsglobenewswire.com - February 29 at 4:05 PMOncternal Therapeutics (NASDAQ:ONCT) Will Have To Spend Its Cash Wiselyfinance.yahoo.com - February 25 at 9:28 AMOncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conferencefinance.yahoo.com - February 6 at 8:35 PMOncternal Therapeutics Inc ONCTmorningstar.com - February 3 at 11:18 PMONCT Jul 2024 7.500 callca.finance.yahoo.com - January 30 at 7:36 PMONCT Apr 2024 2.500 callca.finance.yahoo.com - January 30 at 7:36 PMOncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancerfinance.yahoo.com - January 8 at 9:22 AMmarketbeat.com - January 8 at 6:02 AMOncternal Therapeutics announces a reverse stock splitmsn.com - January 4 at 12:00 PMOncternal Therapeutics Announces Reverse Stock Splitfinance.yahoo.com - January 4 at 12:00 PMOncternal Therapeutics Updates Early Disease Response Data For ONCT-808; Shares Fallnasdaq.com - December 26 at 2:16 PMOncternal Therapeutics Reports Patient Death In Mid-Stage Blood Cancer Study Treated With Second Dose Levelmsn.com - December 26 at 2:16 PMOncternal Therapeutics Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-cell Lymphomafinance.yahoo.com - December 26 at 9:16 AMOncternal Therapeutics Stock (NASDAQ:ONCT) Dividends: History, Yield and Datesbenzinga.com - December 21 at 8:55 AMOncternal Therapeutics upgraded to Buy from Hold at Brooklinerealmoney.thestreet.com - December 4 at 3:26 PMOncternal Therapeutics, Inc. (NASDAQ:ONCT) Q3 2023 Earnings Call Transcriptfinance.yahoo.com - November 11 at 12:00 PMBuy Rating for Oncternal Therapeutics: Promising Clinical Programs and Potential Catalystsmarkets.businessinsider.com - November 11 at 7:00 AMQ3 2023 Oncternal Therapeutics Inc Earnings Callfinance.yahoo.com - November 10 at 3:53 PM Get Oncternal Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (Ad)The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. ONCT Media Mentions By Week ONCT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ONCT News Sentiment▼0.380.58▲Average Medical News Sentiment ONCT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ONCT Articles This Week▼111▲ONCT Articles Average Week Get Oncternal Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: LSTA News CPIX News BNTC News TXMD News FLGC News GDTC News RNXT News LUMO News BIOR News ONTX News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ONCT) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsCollapse of the Petrodollar Colonial MetalsGold Set to EXPLODE!Gold Safe ExchangeShocking: One AI startup's revenue could surge 4,735%Manward Press[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICHe Is Giving Away BitcoinCrypto Swap ProfitsElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncternal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
